Stockreport

Late-stage study of Corcept's relacorilant in Cushing's syndrome underway [Seeking Alpha]

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF Dosing is underway in a Phase 3 clinical trial, GRACE , evaluating Corcept Therapeutics' ( CORT ) lead candidate relacorilant in patient with Cushing's s [Read more]